Academic literature on the topic 'Mental Chemotherapy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Mental Chemotherapy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Mental Chemotherapy"
1
Meymandi, Assad. "Mental Exercises Counter Chemotherapy." Psychiatric News 42, no. 7 (April 6, 2007): 27. http://dx.doi.org/10.1176/pn.42.7.0027.
Full text
2
Redd, William H., Mark R. Dadds, Ann D. Futterman, Kathryn L. Taylor, and Dana H. Bovbjerg. "Nausea induced by mental images of chemotherapy." Cancer 72, no. 2 (July 15, 1993): 629–36. http://dx.doi.org/10.1002/1097-0142(19930715)72:2<629::aid-cncr2820720249>3.0.co;2-7.
Full text
3
Anand, Ajay, William H. Redd, Mark R. Dadds, Ann D. Futterman, Kathryn L. Taylor, and Dana H. Bovbjerg. "Nausea induced by mental images of chemotherapy." Cancer 73, no. 3 (February 1, 1994): 755–56. http://dx.doi.org/10.1002/1097-0142(19940201)73:3<755::aid-cncr2820730344>3.0.co;2-r.
Full text
4
Sengar, Vaishali. "Topical Dosage for Treatment of Chemotherapy- Induced Peripheral Neuropathy." International Journal of Psychosocial Rehabilitation 23, no. 4 (December 30, 2019): 1766–78. http://dx.doi.org/10.37200/ijpr/v23i4/pr190507.
Full text
5
Knudsen, Peder. "Chemotherapy With Neuroleptics." Acta Psychiatrica Scandinavica 72, S322 (July 1985): 51–75. http://dx.doi.org/10.1111/j.1600-0447.1985.tb08540.x.
Full text
6
Brandão, D., T. Assunção, and H. Almeida. "Invisible Effects of Chemotherapy." European Psychiatry 41, S1 (April 2017): S668. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1138.
Full textAbstract:
IntroductionChemotherapy is an essential component in the treatment and alleviation of oncological diseases. To your application are associated, as well as systemic effects, cognitive impairment in patients. These changes have received increasing attention due to the impact on quality of life of cancer survivors.ObjectivesThis study aims to evaluate the current evidence on the association between chemotherapy and cognitive impairment in cancer patients, especially in the areas affected cognitive function, possible mechanisms of action and consequences on the quality of life of these patients and the importance of identifying strategies intervention in order to minimize these effects.MethodsWe conducted a literature review from literature articles addressing this topic with use of databases: Medline and Pubmed. The following keywords were used: “chemobrain”, “cognitive dysfunction”, “chemotherapy”.ResultsAlthough some states have not found differences, several studies have shown that chemotherapy has implications cognitively. Underlying etiology remains unknown, and proposed several mechanisms to explain these changes: neurotoxicity, microvascular damage and inflamamatory response. Cognitive impairment has significant implications in the daily life of patients both personally, socially and labour. The therapeutic approach focuses on the patient and family education, coping strategies, cognitive rehabilitation and cognitive behavioural therapy.ConclusionsIt is vital to educate patients about the possibility of cognitive change as effect of chemotherapy as well as health professionals in the early identification of these changes. It is essential developing specific intervention strategies to improve the quality of life of the oncologic patient during and after treatment.Disclosure of interestThe authors have not supplied their declaration of competing interest.
7
Deleemans, Julie M., Kirsti Toivonen, Raylene A. Reimer, and Linda E. Carlson. "The Chemo-Gut Study: A Cross-Sectional Survey Exploring Physical, Mental, and Gastrointestinal Health Outcomes in Cancer Survivors." Global Advances in Health and Medicine 11 (January 2022): 2164957X2211459. http://dx.doi.org/10.1177/2164957x221145940.
Full textAbstract:
Background Cancer treatments, such as chemotherapy, may adversely affect gastrointestinal (GI), physical and mental health in survivors of cancer. Objective This study investigated associations between GI, mental and physical health outcomes, and cancer treatment-related variables, such as chemotherapy, in adult cancer survivors. Methods A one-time cross-sectional survey with patient-reported outcomes was used. Cancer survivors (N = 317) aged ≥18 years, living in Canada, who completed cancer treatments were included. Descriptive statistics, correlation, and linear regression analyses are reported. Results Mean age at diagnosis was 40.90 ± 15.40 years. Most survivors received chemotherapy (86.1%). Persistent GI symptoms include constipation (53.6%), diarrhea (50.5%), and bloating/pain (54.9%). Mean GI symptom duration was 30.53 ± 33.42 months. Severity of GI symptom interference was moderate to extreme for 51.9% of survivors. Compared to normative values of 50 in healthy people, survivors scored poorer for mental health (M = 42.72 ± 8.16) and physical health (M = 45.55 ± 7.93), and reported more belly pain (M = 56.10 ± 8.58), constipation (M = 54.38 ± 6.81), diarrhea (M = 55.69 ± 6.77), and gas/bloating (M = 56.08 ± 8.12). Greater GI symptom severity was associated with poorer mental and physical health ( P < .01). Chemotherapy was associated with increased belly pain ( B = 4.83, SE = 1.65, P < .01) and gas/bloating ( B = 3.06, SE = 1.45, P = .04). Conclusion We provide novel evidence that many cancer survivors experience chronic, moderate to severe GI symptoms lasting for years after cancer treatment, which are associated with worse mental and physical health. Chemotherapy is associated with specific GI symptoms. Integrative therapies are needed to address GI symptoms in cancer survivors.
8
Nieboer, Peter, Ciska Buijs, Sjoerd Rodenhuis, Caroline Seynaeve, Louk V. A. M. Beex, Elsken van der Wall, Dick J. Richel, et al. "Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study." Journal of Clinical Oncology 23, no. 33 (November 20, 2005): 8296–304. http://dx.doi.org/10.1200/jco.2005.10.167.
Full textAbstract:
PurposeDetermine whether standard or high-dose chemotherapy leads to changes in fatigue, hemoglobin (Hb), mental health, muscle and joint pain, and menopausal status from pre- to post-treatment and to evaluate whether fatigue is associated with these factors in disease-free breast cancer patients.Patients and MethodsEight hundred eighty-five patients were randomly assigned between two chemotherapy regimens both followed by radiotherapy and tamoxifen. Fatigue was assessed using vitality scale (score ≤ 46 defined as fatigue), poor mental health using mental health scale (score ≤ 56 defined as poor mental health) both of Short-Form 36, muscle and joint pain with Rotterdam Symptom Checklist, and Hb levels were assessed before and 1, 2, and 3 years after chemotherapy.ResultsFatigue was reported in 20% of 430 assessable patients (202 standard-dose, 228 high-dose) with at least a 3-year follow-up, without change over time or difference between treatment arms. Mean Hb levels were lower following high-dose chemotherapy. Only 5% of patients experienced fatigue and anemia. Mental health score was the strongest fatigue predictor at all assessment moments. Menopausal status had no effect on fatigue. Linear mixed effect models showed that the higher the Hb level (P = .0006) and mental health score (P < .0001), the less fatigue was experienced. Joint (P < .0001) and muscle pain (P = .0283) were associated with more fatigue.ConclusionIn 3 years after treatment, no significant differences in fatigue were found between standard and high-dose chemotherapy. Fatigue did not change over time. The strongest fatigue predictor was poor mental health.
9
Campbell, Gillian, and Eugene Wong. "Clozapine and chemotherapy: a dangerous couple or a necessary partnership?" BMJ Case Reports 13, no. 12 (December 2020): e238377. http://dx.doi.org/10.1136/bcr-2020-238377.
Full textAbstract:
A 48-year-old man with a history of schizophrenia was diagnosed with B-cell lymphoma of the small bowel. Neutropaenia occurred secondary to chemotherapy, which led to clozapine being discontinued, which resulted in the deterioration of his mental state, in turn, affecting the treatment of lymphoma. Clozapine was later reintroduced alongside granulocyte colony-stimulating factor, leading to improved mental state without any further incidences of neutropaenia.
10
Shafiee, H., R. Hassanzadeh, D. Ghasemian, and S. Ebrahimi. "Comparing the Mental Health and Hope between Radiotherapy and Chemotherapy Patients." International Journal of Psychology and Psychiatry 2, no. 1 (2014): 25. http://dx.doi.org/10.5958/j.2320-6233.2.1.004.
Full textDissertations / Theses on the topic "Mental Chemotherapy"
1
Duncan, Stel S. "A meta-analysis of Prozac and three psychotherapies in the treatment of unipolar major depression." Diss., Virginia Tech, 1994. http://hdl.handle.net/10919/37453.
Full text
2
Shirama, Flávio Hiroshi. "Transtornos mentais comuns, uso de psicofármacos e qualidade de vida em pacientes oncológicos ambulatoriais." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/22/22131/tde-28112017-163739/.
Full textAbstract:
Este estudo teve como objetivos estimar prevalências de Transtornos Mentais Comuns (TMC) e de uso de psicofármacos em pacientes oncológicos em tratamento ambulatorial; verificar associações entre TMC e variáveis sociodemográficas, culturais, uso de psicofármacos e histórico de saúde; verificar associações entre uso de psicofármacos e variáveis sociodemográficas, culturais e histórico de saúde e; avaliar a qualidade de vida e fatores associados nestes pacientes. Trata-se de estudo transversal no qual foram entrevistados 403 pacientes do setor de quimioterapia de um hospital oncológico, com a utilização de questionário para coleta de dados sociodemográficos, culturais, histórico de saúde e uso de psicofármacos, além de instrumentos de rastreamento de Transtornos Mentais Comuns (SRQ- 20) e de avaliação de qualidade de vida (EORTC QLQ-C30). Para a abordagem de TMC e uso de psicofármacos como variáveis dependentes, foram realizadas as análises univariada (teste de Qui-quadrado) e regressão logística multivariada. A comparação dos grupos em relação à idade foi realizada por meio dos testes de Mann-Whitney e de Kruskal-Wallis. Para análise da qualidade de vida foi proposto modelo de regressão quantílica. Para todas as comparações adotou-se nível de significância de 5%. Os resultados revelaram prevalência de 31,5% de TMC e 25,8% de uso de psicofármacos. Por meio do teste Qui-quadrado identificou-se associação entre TMC e as variáveis sexo, escolaridade, renda familiar, uso de psicofármaco e histórico de cirurgia oncológica. Na regressão logística as variáveis sexo (OR=4,86; IC95% 2,27-10,42) e presença de comorbidades (OR= 2,12; IC95% 1,13-4,0) mostraram-se associadas a TMC. O uso de psicofármacos associou-se a sexo, situação de trabalho, histórico de cirurgias oncológicas, tempo de tratamento e comorbidades. Verificou se que as variáveis sexo (OR= 4,29; IC95% 2.03-9,08), situação de trabalho (OR=0,33; IC95% 0,15-0,75) e comorbidades (OR= 1,73; IC95% 1,05-2,84) exerceram contribuição estatisticamente significativa no modelo de regressão. Casos positivos para TMC apresentaram piores escores de qualidade de vida/saúde global e, entre esses, os que usavam psicofármacos apresentaram pior qualidade de vida do que os que não usavam. Identificou-se pior qualidade de vida em homens e em pessoas com baixo nível educacional. Os casos positivos para TMC apresentaram, também, piores capacidades física, emocional, cognitiva e social, pior desempenho de papel e maior proeminência dos sintomas fadiga, dor, insônia, perda de apetite e dispneia. Pacientes que usavam psicofármacos apresentaram piores funcionamentos físico, emocional e social e maior proeminência de fadiga e dispneia do que aqueles que não usavam tais medicamentos. Indivíduos sem renda ou com rendas mais baixas apresentaram piores funcionamentos cognitivo e social e maior proeminência de dor, insônia e dificuldades financeiras. Pacientes com nível de escolaridade mais baixo apresentaram pior funcionamento social e os analfabetos apresentaram maior proeminência de insônia. A idade influenciou no funcionamento físico. Pacientes que não tinham religião apresentaram maior proeminência de falta de apetite. De forma pioneira, este estudo identificou a forte influência de TMC e uso de psicofármacos na qualidade de vida de pacientes oncológicos que estavam realizando quimioterapia, agregando informações importantes à literaturaThe objective of this study was to estimate the prevalence of Common Mental Disorders (CMD) and the use of psychotropic drugs in oncology patients undergoing outpatient treatment; verify sociodemographic and cultural variables, the use of psychoactive drugs and health history in association with CMDs; verify associations between the use of psychoactive drugs and sociodemographic, cultural and health history variables; evaluate the quality of life and factors associated within these patients. This was a cross-sectional study in which 403 patients from the chemotherapy sector of a cancer hospital were interviewed, using a questionnaire to collect sociodemographic, cultural data, health history and use of psychotropic drugs, as well as screening instruments for Mental Disorders Common (SRQ- 20) and Quality of Life assessment (EORTC QLQ-C30). For the approach to CMD and the use of psychotropic drugs as dependent variables, multivariate logistic regression and univariate analysis (Chi-square test) were used. A group comparison in relation to age was performed using the Mann-Whitney and Kruskal-Wallis tests. For Quality of Life analysis, a quantile regression model was proposed. For all comparisons, a significance level of 5% was adopted. The results showed a prevalence of 31.5% CMD and 25.8% use of psychoactive drugs. The Chi-square test identified an association between CMD and the variables of gender, schooling, family income, use of psychoactive drugs and history of oncological surgery. In the logistic regression the gender variables (OR=4.86; IC95% 2.27-10.42) and presence of comorbidities (OR= 2.12; IC95% 1.13-4.0) showed to be associated with CMD. The use of psychoactive drugs was associated with gender, employment status, history of oncologic surgeries, time of treatment and comorbidities. It was verified that the variables in gender (OR= 4.29; IC95% 2.03-9.08), employment status (OR=0.33; IC95% 0.15-0.75) and comorbidities (OR= 1.73; IC95% 1.05-2.84) exerted a significant statistical contribution to the regression model. Positive cases for CMD showed the lowest scores in regards to quality of life/overall health and among these, those using psychotropic drugs showed a lower quality of life than those who did not. A poor quality of life was identified in men and in people that had a low education level. Positive cases for CMD also showed the lowest in physical, emotional, cognitive and social abilities, poor role performance and greater prominence of the symptoms of fatigue, pain, insomnia, loss of appetite and dyspnea. Patients using psychoactive drugs had the worse physical, emotional, and social functions and greater prominence of fatigue and dyspnea than those who did not use such medications. Individuals without income or with low income showed the lowest cognitive and social functioning ability and a greater prominence of pain, insomnia and financial difficulties. Patients with a lesser level of education presented low social functioning abilities and those who were illiterate, presented a greater prominence of insomnia. Age had an influence in physical function abilities. Patients who did not have a religion showed a greater loss of appetite. In a pioneering way, this study has identified the strong influence of CMD and the use of psychoactive drugs on the quality of life of oncology patients undergoing chemotherapy, adding important research information to current study literature
3
Guess, Gloria Michelle. "Relationship Between Cancer-Related Fatigue and Depression: A Pilot Study." Scholar Commons, 2011. http://scholarcommons.usf.edu/etd/3132.
Full textAbstract:
Abstract
Fatigue is one of the most bothersome symptoms reported by patients diagnosed with cancer, and research indicates that the majority of patients receiving chemotherapy report symptoms of fatigue. Fatigue can have an effect on quality of life; therefore, it is essential that healthcare providers gain a better understanding and recognition of fatigue.
Fatigue can also be a symptom of depression. Depression is another prominent symptom reported by patients diagnosed with cancer. Unfortunately, there are similarities between the symptoms of depression and fatigue making it difficult for health care providers to distinguish between the two. This study utilizes the subscale of the Hospital Anxiety and Depression Scale and the Multidimensional Fatigue Scale-Short Form to further investigate the relationship between cancer-related fatigue and depression.
The convenience sample consisted of 30 chemotherapy patients being treated at an outpatient infusion center in a comprehensive cancer center in southwest Florida. All participants were between the ages of 26 and 74, and had been receiving chemotherapy for a minimum of three weeks; none had been diagnosed with chronic fatigue syndrome, or were currently being treated with radiation.
The participants in the study self-rated their fatigue on a Likert-type scale of 0-10. The mean score on the self-rated fatigue scale was 4.03 (SD= 2.76). This study supports prior studies in which chemotherapy patients report mild to severe levels of fatigue.
The mean score on the depression subscale of the Hospital Anxiety and Depression subscale was 4.53 (SD=4.2). A statistically significant correlation was noted between cancer-related fatigue and depression, utilizing the Hospital Anxiety and Depression subscale score and Multidimensional Fatigue Inventory-Short Form total scores (r=.676, p=.000).
This study provides evidence that tools such as the Hospital Anxiety and Depression Scale and the Multidimensional Fatigue Inventory-Short Form can aid researchers and providers in distinguishing between fatigue and depression. Using these instruments in future research and practice may help avoid the overlap in symptoms of fatigue and depression.
These study results support findings from previous studies indicating a moderate correlation between cancer-related fatigue and depression. This study addresses the correlation between cancer-related fatigue and depression in chemotherapy patients which may improve nursing assessment of fatigue and depression in this population. Findings suggest the need for ongoing research focusing on cancer-related fatigue and depression as well as appropriate pharmacological and non-pharmacological interventions to improve the quality of life of this patient population.
4
Patterson, Nona L. "Providing behavioral data to physicians for enhancing medication treatment for chronically mentally disabled individuals." Scholarly Commons, 1987. https://scholarlycommons.pacific.edu/uop_etds/2140.
Full textAbstract:
Physicians are often unaware of mentally disabled outpatients' symptomatic behaviors that are relevant to their medication prescriptions. Such information is available to the clients' residential care providers . The present study trained clients' residential care providers in data collection and provided these data to physicians. It was predicted that these data would improve medication treatment for these clients and consequently lead to a decrease in client's symptomatic behaviors . The results did not confirm the predictions; the data provided to physicians on clients' between- visit behaviors had no measured effect on the physicians' treatment of these clients, although the physicians reported positive attitudes about the helpfulness and utility of ·the system .
5
CHEN, WEN-YU, and 陳汶鈺. "Measurement and Analysis of Nursing Mental Workload in Chemotherapy Medication Administration." Thesis, 2019. http://ndltd.ncl.edu.tw/handle/8mx8qp.
Full textAbstract:
碩士國立臺北科技大學
工業工程與管理系
107
The highest incidence of drug events occurs in the medical incident, with the highest level of patient injury is caused by high-alert medications. Currently, medical institutions believe that most of the causes of medical incident are human errors, but from the perspective of human factors, human error is not the root cause and requires more in-depth analysis. Therefore, the purpose of this study is to analyze the tasks of chemotherapy medication administration for nurses and measures the mental workload of each task. The research method divided the chemotherapy medication administration into 11 tasks by hierarchical task analysis, and then measured the various tasks for the 11 tasks. The mental workload of each task was measured by the McCracken-Aldrich technique which was evaluated by human factor experts and the NASA-TLX questionnaire subjectively assessed by the nurses. The study will propose improvements in the four dimensions of the McCracken-Aldrich technique (visual, auditory, cognitive, and psychomotor) and the validity of this technique will be verified by the NASA-TLX questionnaire. In addition, the nurses also subjectively assessed the potential hazard of each task based on the hazard scores of the Healthcare Failure Mode and Effects Analysis (HFMEA). The results of the study showed that the scores of mental workload assessed by experts were significantly correlated with the scores of the NASA-TLX questionnaire, indicating that the McCracken-Aldrich technique could effectively measure the mental workload of the nurse. According to the tasks of the NASA-TLX questionnaire, the mental workload total scores and the hazard score divided the tasks into three categories (high mental workload high hazard score, high mental workload low hazard score and low mental workload low hazard score), and suggestions for improving the operating equipment, physical and social environment. Subsequent research and directions can explore the situation of multitasking with the nurses, and expand this research method to evaluate the medical procedures such as prescribing by doctors and dispensing by pharmacists to improve medical quality and patient safety.
Books on the topic "Mental Chemotherapy"
1
Chemotherapy in psychiatry: Principles and practice. Cambridge, Mass: Harvard University Press, 1985.
Find full text
2
Baldessarini, Ross J. Chemotherapy in psychiatry: Principles and practice. Cambridge (Mass.): Harvard University, 1985.
Find full text
3
Wegmann, Joseph. Psychopharmacology: Straight talk on mental health medications. 2nd ed. Eau Claire, Wis: Premier Pub. & Media, 2011.
Find full text
4
Broken brains or wounded hearts: What causes mental illness. Santa Ana, Calif: Kevco Pub., 1996.
Find full text
5
Rosen, Hugo. Clinical psychopharmacology for the busy practitioner. Edited by Wills Susan. Daytona Beach, Fla: Pearce Publishers, 1992.
Find full text
6
Psychopharmacology demystified. Clifton Park, NY: Delmar Cengage Learning, 2011.
Find full text
7
University of Michigan. School of Social Work., ed. Psychiatric medications: A guide for mental health professionals. Newbury Park, Calif: Sage Publications, 1990.
Find full text
8
1958-, Bottiglieri Teodoro, and Colman Carol, eds. Stop depression now: SAM-e, the breakthrough supplement that works as well as prescription drugs in half the time, with no side effects. New York: Putnam, 1999.
Find full text
9
Byck, Robert. Treating mental illness. London: Burke, 1988.
Find full text
10
Treating mental illness. New York: Chelsea House Publishers, 1986.
Find full textBook chapters on the topic "Mental Chemotherapy"
1
Marilyn, Weaver Lewis, Wu Liyun, and Allan Hagen Zachary. "How Understanding Genetics Can Benefit Mental Health Clinicians." In STEM-H for Mental Health Clinicians, 1—C1P29. Oxford University PressNew York, 2023. http://dx.doi.org/10.1093/oso/9780197638514.003.0001.
Full textAbstract:
Abstract STEM-H for Mental Health Clinicians, Chapter 1, introduces the science of genetics and its role in behavior. Classic experiments testing the influence of nature or nurture as they pertain to alcohol misuse and dependency are described. The gene–environment relationship of behavioral disorders is discussed with an emphasis on genotypic and phenotypic expression. Radiation exposure and carcinogens and their relationship to genetic injuries are presented. Asynchronous and synchronous communication technologies are introduced. Engineering of medications for chemotherapy of genetic-based disorders is discussed. The Asian flushing reaction is introduced as example of genetic predisposition to abstinence from alcohol. Ambiguous loss and stigmatized grief as reactions of families with a child expressing a genetic mutation are introduced.
2
Simon, Chantal, Hazel Everitt, Françoise van Dorp, and Matt Burkes. "Cancer and palliative care." In Oxford Handbook of General Practice, 1019–48. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199671038.003.0028.
Full textAbstract:
Principles of cancer care Surgery for cancer Chemotherapy Radiotherapy Palliative care in general practice Pain and general debility Anorexia, nausea, and vomiting Other GI problems Skin, neurological, and orthopaedic problems Respiratory problems Haematological and vascular problems Problems with mental well-being The last 48 hours Syringe drivers...
3
Haber, Sandra. "Counseling Women with Breast Cancer." In Handbook of Private Practice, 669–73. Oxford University Press, 2017. http://dx.doi.org/10.1093/med:psych/9780190272166.003.0053.
Full textAbstract:
Counseling women with breast cancer is a niche practice that is a significant but often overlooked part of the breast cancer treatment protocol. With appropriate training and experience, mental health clinicians can facilitate medical decision making, manage the side effects of treatments such as chemotherapy and mastectomy, and improve coping skills for posttreatment reactions. Mental health clinicians can also provide significant interventions with the patient’s partner, children, parents, and friends at each stage of the treatment process. This chapter describes the author’s involvement and development of this niche specialty, the joys and sorrows of work in this area, and the business obstacles that can be encountered and overcome. Resources to assist those interested in developing this niche area of practice are provided.
4
"Central nervous system cancer." In Oxford Handbook of Cancer Nursing, edited by Mike Tadman, Dave Roberts, Mark Foulkes, Mike Tadman, Dave Roberts, and Mark Foulkes, 311–22. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198701101.003.0023.
Full textAbstract:
This chapter looks at tumours of the central nervous system (CNS), covering their classification and treatment and moving on to examining the nursing care of these individuals. The primary treatment modality is surgery, supported by radiotherapy and chemotherapy, although outcomes of treatment can be very poor. Because of this, and the high levels of physical and mental disability caused by CNS tumours, this patient group can present real challenges in terms of nursing care. The management of cerebral oedema is addressed, alongside the importance of a multidisciplinary approach to the care of these complex patients. As well as primary brain tumours, the much more common presentation of brain metastases is discussed within the chapter, and a brief outline of nursing management of patients with brain metastases and the challenges faced is given.
5
Zhou, Zhiwei, and Ping Xu. "Characteristics of Magnetic Resonance Spectroscopy in Toxic Leukoencephalopathy." In Neuroimaging - New Insights [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.106919.
Full textAbstract:
Toxic leukoencephalopathy (TLE) refers to a series of diseases with central nervous system damage caused by poisoning of various toxic substances, including medications, gases, drugs, and ethanol as the main clinical manifestation. TLE mainly causes the damage to white matter fibers and subcortical gray matter nuclei, including basal ganglia nuclei, thalamus and brainstem nuclei (substantia nigra red nucleus), as well as cerebellar dentate nucleus, which manifests as altered mental status, epilepsy, paresthesia, hemiparesis, tetraparesis, or even death. Magnetic resonance spectroscopy (MRS) has contributed to understanding the etiology and stage of TLE. Moreover, the change of brain metabolites, which can be evaluated by MRS, provides additional information for confirming diagnosis, monitoring disease progression, and informing treatment response. In order to describe the MRS characteristics of TLE caused by different etiologies, we will review the spectroscopy change of TLE which is associated with psychoactive substances, immunosuppressant, chemotherapy, and environment (PICE). Therefore, we reviewed the MRS characteristics of heroin-induced TLE, methadone-induced TLE, oxycodone-induced TLE, Wernicke encephalopathy, Marchiafava-Bignami disease, methotrexate-related TLE, metronidazole-induced TLE, carbon monoxide-related encephalopathy, and toluene TLE in this chapter.
6
"Cancer-related fatigue." In Oxford Handbook of Cancer Nursing, edited by Mike Tadman, Dave Roberts, Mark Foulkes, Mike Tadman, Dave Roberts, and Mark Foulkes, 519–24. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198701101.003.0042.
Full textAbstract:
Fatigue is one of the most common and distressing symptoms experienced by people with cancer, occurring in up to 80% of people having treatment. Cancer-related fatigue (CRF) is characterized by a subjective feeling of tiredness, weakness, or lack of energy. It is different from the usual tiredness experienced after exertion, as it is not relieved by rest. It tends to be pervasive and affects both mental processes, like concentration and attention, and physical processes, restricting activities and potentially leading to social isolation. It is associated with all forms of cancer treatments, including surgery, radiotherapy, chemotherapy, and biological therapies. In spite of this, the underlying processes and pathophysiology of CRF are not fully understood. Assessment of fatigue can be based on simple questions about its presence and the severity and effects on function, rating on a scale of 0 to 10, or it can be rated by the patient as mild, moderate, or severe. Those reporting moderate to severe fatigue should receive a more detailed fatigue assessment. Many of the fatigue management strategies are psychosocial or behavioural, so education and counselling are central to the effective management of fatigue. Psychosocial interventions include education, exercise and activity, energy conservation, sleep hygiene, attention-restoring interventions, and psychological treatments. The most commonly used pharmacological approaches include: psychostimulants, antidepressants, corticosteroids, treatments for anaemia, and progestogens.
7
Lyketsos, Constantine G. "Brain Tumors, Systemic Lupus Erythematosus, HIV/AIDS, and Wilson’s Disease." In Psychiatric Aspects of Neurologic Diseases. Oxford University Press, 2008. http://dx.doi.org/10.1093/oso/9780195309430.003.0021.
Full textAbstract:
This chapter deals with four diseases affecting the central nervous system (CNS) for which neurologists are primarily involved as consultants. It follows the same approach as the chapters that focus on single diseases but does so more briefly. Brain tumors are estimated to have an incidence of 12/100,000 per year (Scharre, 2000). The incidence is highest in old age, peaking between 60 and 80 years of age. Almost 50% of intracranial tumors are gliomas, 10% to 15% are meningiomas, 5% to 7% are pituitary adenomas, and 5% to 6% are metastatic tumors. Brain tumors produce signs and symptoms in a variety of ways, including direct invasion, compression, hemorrhage, and edema. Motor, sensory, visual, and gait disturbances are frequent manifestations of brain tumors. In addition, headache and focal or generalized seizures are quite common. The psychiatric manifestations of brain tumors reflect their location; the type of brain damage they produce; patients’ reactions to their symptoms or diagnosis; and the effects of treatments such as steroids, chemotherapy, and radiation. Tumors in specific brain regions have been linked to specific psychiatric manifestations. Frontal lobe tumors are most closely associated with behavioral changes,sometimes referred to as the frontal lobe syndrome or executive dysfunction syndrome. Temporal lobe tumors are most closely associated with personality change, irritability, and hallucinations (especially auditory), as well as with a variety of language disorders. Patients with language disorders associated with temporal lobe tumors can experience catastrophic reactions when their deficits interfere with communication. Parietal lobe tumors typically are associated with cognitive deficits such as apraxia, neglect syndromes of the contralateral body or space, and unformed visual hallucinations such as streaks or flashes of light. When evaluating brain tumor patients with psychiatric symptoms and signs, careful evaluation and differential diagnosis are critical. In hospitalized and seriously ill patients, it is especially important to rule out delirium, particularly when the psychiatric phenomena are intermittent and vary in intensity. Serial observations and repeated mental status examinations are the basis for the diagnosis of delirium, but an electroencephalogram (EEG) is also helpful, because in most cases of delirium it reveals generalized slowing involving brain areas far from the location of the brain tumor.
Conference papers on the topic "Mental Chemotherapy"
1
Pâslaru, Ana-Maria, Ana Fulga, Elena Niculet, Laura Florentina Rebegea, Iuliu Fulga, and Anamaria Ciubara. "SUPRACLAVICULAR AND CERVICAL LYMPH NODE METASTASES HAVING CERVICAL CANCER AS STARTING POINT. CASE PRESENTATION." In The European Conference of Psychiatry and Mental Health "Galatia". Archiv Euromedica, 2023. http://dx.doi.org/10.35630/2022/12/psy.ro.10.
Full textAbstract:
Introduction: Cervical cancer is the fourth most frequently found cancer among women worldwide. Numerous studies have underlined that persistent infection with human papilloma virus is the most important risk factor, two strains of the same virus – 16 and 18 being responsible for approximately 70% of the cases. Cervical cancer rarely metastasizes in the cervical lymph nodes and this indicates a poor prognosis. Literature data reports an incidence for left supraclavicular M1LYm of 0.1-1.5%. Material and Method: We bring attention to the case of a 44-year-old patient from the rural area who was diagnosed in January 2019 with stage IIIB cervical cancer, represented morphologically by a poorly differentiated squamous cell carcinoma. When admitted, the patient presented clinically with vaginal hemorrhage, intense abdominal and pelvic pain, fatigue, a dynamic, significant weight loss. The physiological personal history revealed nine pregnancies, the first one when she was 16. After pretherapeutic evaluation, the multidisciplinary committee decides performing simultaneous radio-chemotherapy with platinum salts. During the second week of treatment clinical examination revealed left cervical and supraclavicular adenopathy, both documented through imaging evaluation. Lymph node biopsy is done and its histopathological aspect, correlated with the immunohistochemistry profile supports the diagnosis of poorly differentiated squamous cell carcinoma lymph node metastasis. The initial treatment scheme is maintained, the patient being discharged with clinical remission of cervical and supraclavicular lymph node metastasis. Conclusions: The peculiarity of the case is determined by the distant metastases in the left cervical and supraclavicular lymph nodes, a rare finding during treatment, which was associated with a poor prognosis; in this case treatment was done for palliative purposes. Rapid diagnosis is the main factor that conditions the therapeutic results and chances for healing.
2
Pâslaru, Ana Maria, Ana Maria Fătu, Alexandru Nechifor, Laura Florentina Rebegea, Diana Bulgaru Iliescu, and Anamaria Ciubara. "PSYCHO-ONCOLOGY. CASE PRESENTATION." In The European Conference of Psychiatry and Mental Health "Galatia". Archiv Euromedica, 2023. http://dx.doi.org/10.35630/2022/12/psy.ro.35.
Full textAbstract:
Increased survival of oncology patients brings to attention new aspects of adverse effects due to antineoplastic treatment. Psychiatric disorders, cardiovascular disorders as well as the progressive incidence of multiple primary neoplasia are some of the most common side effects. Aim: Care of the oncology patient undergoes an important period of change, from the management of tumor disease to the multidisciplinary approach, centered on improving the quality of life. Method: We present the case of a 75-year-old patient, whose personal pathological history reveals the presence of a diagnosis of left testicular seminoma, in 1978, for which he received radiochemical therapy. An oncological patient under long-term medical supervision for several decades is diagnosed in November 2017 with urothelial carcinoma, infiltrative, invasive in his own muscle patch, pT2NxMx. Approximately 40 years later, the second neoplastic site, the malignant bladder tumor, appears. Facing this diagnosis, the patient becomes anxious, anticipates catastrophic consequences, isolates himself. The family and friends support is essential in these moments, the patient tries cognitive-behavioral psychotherapy, as well as various relaxation techniques, which have positive results for the patient attitude towards the disease. He admits, to complete staging, to follow the recommendations of the oncologist, perform proton emission tomography, which detects the presence of two lesions on the right lung. In January 2018, the surgical intervention is done by straight thoracotomy, atypical upper lobe resection and inferior lobectomy is performed. The histopathological and immunohistochemical results describe the presence of the third primary adenocarcinoma neoplasia. The initial emotional reaction is one of anger, denial, followed by demoralization, easy crying, sadness. The patient is examined by the psychiatrist, thus receiving the diagnosis of a severe depressive episode without psychotic symptoms. He follows an anxiolytic, antidepressant, sedative treatment but continues also the cognitive-behavioral therapy. The patient shows good compliance with psychopharmacological treatment and accepts adjuvant chemotherapy courses, which are well tolerated. Throughout the antineoplastic therapy, there was a close collaboration between the psychiatrist and the oncologist, to avoid drug interactions that could have led to interruption of the treatment. Under the oncology supervision, the patient receives another bad news, in September 2018, the fourth neoplastic localization, the prostatic adenocarcinoma pT2bN0M0, is discovered. In this case, in the presence of the combination of synchronous and methacrone tumors, the patient's psyche is deeply affected, continuing the psychopharmacological treatment. Conclusions: Psychiatric disorders are common among oncological patients, and they may suffer serious impairments in quality of life and treatment compliance, psycho-oncological collaboration being indispensable for the success of antineoplastic treatment.
3
Dewi, Rizka Amalia, Ambar Mudigdo, and Eti Poncorini Pamungkasari. "The Biopsychosocial Determinants of Quality of Life in Patients with Breast Cancer: A Multilevel Logistic Regression Evidence from Surakarta, Central Java." In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.01.47.
Full textAbstract:
ABSTRACT Background: A cancer diagnosis and its treatment can be expensive. So that cancer patients may suffer from mental and physical problems. Quality of life (QOL) is a major concern of patients with terminal cancer. This study aimed to investigate the biopsychosocial determinants of quality of life in patients with breast cancer. Subjects and Method: This was a cross sectional study. A sample of 200 patients with breast cancer was selected by a simple random sampling. The dependent variable was quality of life. The independent variables were age, marital status, stage of cancer, chemotherapy, length of disease, coping strategy, family income, and modal social. Quality of life was measured by WHO-QOL-BREF. The other variables were collected by a questionnaire. The data were analyzed by a multiple logistic regression run on Stata 13. Results: Strong modal social (b= 2.52; 95% CI= 0.82 to 4.22; p= 0.003), complete chemotherapy (b= 1.65; 95% CI= -0.05 to 3.35; p= 0.057), length of diagnosis ≥24 months (b= 2.39; 95% CI= 0.69 to 4.22; p= 0.006), family income ≥Rp 5,600,000 (b= 2.94; 95% CI= 1.24 to 4.64; p= 0.001), and good coping strategy (b= 1.70; 95% CI= 0.11 to 3.29; p= 0.036) increased quality of life of patients with breast cancer. Late stage of cancer (b= -2.09; 95% CI= -3.78 to -0.40; p= 0.015) and depression (b= -2.48; 95% CI= -4.26 to -0.69; p= 0.001) decreased quality of life of patients with breast cancer. Age decreased quality of life (b= -0.87; 95% CI= -2.94 to 2.77; p= 0.952), but it was statistically non-significant. Marital status increased quality of life (b= 1.32; 95% CI= -0.35 to 2.99; p= 0.123), but it was statistically non-significant. Conclusion: Strong modal social, complete chemotherapy, length of diagnosis ≥24 months, family income ≥Rp 5,600,000, and good coping strategy increase quality of life of patients with breast cancer. Late stage of cancer and depression decrease quality of life of patients with breast cancer. Age decreases quality of life, but it is statistically non-significant. Marital status increased quality of life, but it is statistically non-significant. Keywords: quality of life, breast cancer Correspondence: Rizka Amalia Dewi. Masters Program in Public Health, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta, Central Java 57126, Indonesia. Email: drizkaez@gmail.com. Mobile: +6282313121768. DOI: https://doi.org/10.26911/the7thicph.01.47
4
Gencheva, Nezabravka. "PHYSIOTHERAPY FOR COLON CANCER IN THE EARLY POSTOPERATIVE PERIOD - A CASE REPORT." In INTERNATIONAL SCIENTIFIC CONGRESS “APPLIED SPORTS SCIENCES”. Scientific Publishing House NSA Press, 2022. http://dx.doi.org/10.37393/icass2022/146.
Full textAbstract:
АBSTRACT Introduction: The Physiotherapy (PT) is an important part of cancer treatment and could be recovery PT, maintenance PT and palliative PT. The aim of the study is to investigate the impact of early postoperative PT on the functional and mental recovery of a 57-year-old patient with colon cancer. Research methods: On the second and seventh postoperative day, we applied a Quality of Recovery-40 (QoR-15) questionnaire, Cumulated Ambulation Score (CAS) and Hospital Anxiety and Depression Scale (HADS) and а 6 min walk-test – on the third and seventh postoperative day. The special PT is used to improve the respiratory function, to alleviate the unpleasant sensations of the gastrointestinal tract, to reduce pain, to restore mobility through training in painless sitting, standing up, and walking, as well as to reduce anxiety and to overcome depressive symptoms. Results: Applied PT in the early postoperative period in severe abdominal surgery for colon cancer prevented postoperative complications. The results show a significant improvement in the studied indicators and good quality of recovery; patient’s independence in standing up, sitting, and walking; pain relief; reduced anxiety and depressive moods. Conclusion: The application of early PT is an important part of patient’s post-surgical care. It helps for optimal recovery and prepares him for the next additional therapies such as chemotherapy, radiation therapy, etc.
5
Gajra, Ajeet, Linda McCall, Hyman B. Muss, Harvey J. Cohen, Aminah Jatoi, Karla V. Ballman, Ann H. Partridge, et al. "Abstract P5-15-07: Association of patient preference for adjuvant chemotherapy (chemo) at baseline (BL) with toxicity, mental health, function, quality of life (QoL) and survival in older women with early stage breast cancer (ESBC) [CALGB 49907 Alliance]." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-15-07.
Full text
6
"The Prevalence of Depressive and Anxious Symptomatology and Use of Antidepressants Among Breast Cancer Patients :A Cross-Sectional Study ." In International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/xsxm3127.
Full textAbstract:
Background: breast cancer is considered as one the most common type among women worldwide and for Jordanian citizens according to Jordan Ministry of health that there was around 1292 (38.4%) new cases of breast cancer reported in 2020, and The diagnosis of breast cancer is usually associated with psychological stress such as Anxiety and depression that is resulting from the diagnosis itself, where if it's was incurable diseases, fear of death, fear of loss, at the end previous studies show that there is a higher prevalence of depressive disorder which is up to two to three times more than the general population. Objective: Our goal in this cross-section study is to find out the prevalence of psychological and depressive disorders correlates to breast cancer (BC) in outpatient and inpatient setting as it was approved that depression is comorbid to cancer that should not be neglected. We also aim to identify risk factors of depression among study participants like cancer stage ( initial or later), income and marital status, and type of intervention chemotherapy or radiation therapy plus their treatment sessions Method: This study was conducted at king Abdullah university hospital in Irbid, King Hussein cancer center (KHCC), and queen Alia Military hospital in Amman, Jordan. More than 400 formed the study sample include inpatient and outpatient setting of breast cancer using in them Depression and anxiety assessment scale. In the inpatient setting The Hospital Anxiety and Depression Scale (HADS) instrument used, which is a 14-question instrument given to patients in a secondary care setting to screen for the presence and severity of depression and anxiety. Also, the beck depression Inventory (BDI) used, which is a self-report rating inventory that measures characteristics, attitudes, and symptoms of depression. In the outpatient setting The PHQ-9 instrument which includes nine questions given to the patient in primary care settings. The anxious symptomatology defined by using the GAD-7 instrument with a total score of 15 and above indicating a case with severe anxious symptomatology. Results: Our study findings demonstrated a higher prevalence of depressive and anxious symptomatology in the inpatient setting and advanced disease stages. In addition, the underutilization of antidepressant therapy was observed. there for we need to consider mental disorder as part of the treatment protocol for breast cancer patient. Keywords: anxiety , antidepressants medications, breast cancer, depression, inpatient, Jordan, outpatient
7
Drexler, Daniel Andras, Tamas Ferenci, Anna Lovrics, and Levente Kovacs. "Comparison of Michaelis-Menten kinetics modeling alternatives in cancer chemotherapy modeling." In 2019 IEEE 13th International Symposium on Applied Computational Intelligence and Informatics (SACI). IEEE, 2019. http://dx.doi.org/10.1109/saci46893.2019.9111543.
Full textReports on the topic "Mental Chemotherapy"
1
Ying, Hongan, Jinfan Shao, Xijuan Xu, Wenfeng Yu, and Weiwen Hong. Perineural Invasion is an Indication of Adjuvant Chemotherapy in Node Negative Colorectal cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0103.
Full textAbstract:
Review question / Objective: Perineural invasion (PNI) is a possible route for metastatic spread in various cancer types, including colorectal cancer (CRC). PNI is linked to poor prognosis. For patients with lymph node positive colorectal cancer, a number of large-scale RCT studies have confirmed that they can benefit from chemotherapy, but there are still many controversies about whether colorectal patients with negative lymph nodes need adjuvant chemotherapy. At present, there is a general consensus that patients with stage II colorectal cancer who have risk factors such as PNI+ need chemotherapy. However, there are many recent literatures that show that patients with stage II colorectal cancer with nerve invasion risk factors can not prolong the OS and DFS of patients. At the same time, chemotherapy increases the toxicity, economic and mental burden of patients. Therefore, we hope to write this review to summarize the current research findings and provide some clinical guidance on whether patients with lymph node negative colon cancer who have perineural invasion should receive chemotherapy. Condition being studied: Patients with high-risk such as PNI+ stage II colon cancer (CC) are recommended to undergo adjuvant chemotherapy (ACT). However, whether such patients can benefit from ACT remains unclear. And recently studies shown that, ACT had no significant benefit among patients with PNI.